ALS is a neurodegenerative disease without therapy to modify its progression and has a fatal outcome. In Lombardy about 1000 affected patients and an expected incidence of 0.8 new cases per day.
The biological mechanisms underlying the disease remain largely unknown, as do the factors that determine clinical and course variability.
INTERSLA aims to expand the knowledge of the pathogenesis of ALS through a pre-clinical approach integrated with advanced technologies of genome editing, animal reproduction, biomarker discovery, molecular biology, big data analysis; to translate knowledge into innovative therapies by identifying new therapeutic targets; to create platforms for biomarker discovery and big data analysis that will draw information from clinical, genetic, tissue, cellular, molecular, biochemical and immunological characterization of patients and animal models.
Consortium: 5 partners from 1 countries
Coordinator of the project: Fondazione IRCCS Istituto Neurologico Carlo Besta, Italy
Funding programme: POR FESR 2014-2020 – Regione Lombardia
Project start: 1st March 2020
End date for the project: 31st May 2022